Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials

Association between organ damage and mortality in systemic lupus erythematosus: a systematic review and meta-analysis

(2020) Irene B Murimi-Worstell et al.   BMJ Open

Trial of Anifrolumab in Active Systemic Lupus Erythematosus

(2019) Eric F. Morand et al.   NEW ENGLAND JOURNAL OF MEDICINE

Responsiveness of clinical and ultrasound outcome measures in musculoskeletal systemic lupus erythematosus

(2018) Khaled Mahmoud et al.   RHEUMATOLOGY

Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus

(2017) Richard Furie et al.   Arthritis & Rheumatology

Systemic lupus erythematosus

(2016) Arvind Kaul et al.   Nature Reviews Disease Primers

Molecular basis for antagonistic activity of anifrolumab, an anti-interferon–α receptor 1 antibody

(2015) Li Peng et al.   mAbs

Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

(2014) Ian N Bruce et al.   ANNALS OF THE RHEUMATIC DISEASES

The Incidence and Prevalence of Systemic Lupus Erythematosus, 2002-2004: The Georgia Lupus Registry

(2013) S. Sam Lim et al.   Arthritis & Rheumatology

Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus

(2012) Yihong Yao et al.   ARTHRITIS RESEARCH & THERAPY

Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years

(2009) S. A. Chambers et al.   RHEUMATOLOGY

Understanding the Epidemiology and Progression of Systemic Lupus Erythematosus

(2009) Guillermo J. Pons-Estel et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM